Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study

Date
2017
Author
Jenkins, David P.
Jais, Xavier
Martin, Nicolas
Madani, Michael M.
Jing, Zhi-Cheng
Kim, Nick H.
Ghofrani, Hossein-Ardeschir
Simonneau, Gerald
D'Armini, Andrea M.
Fedullo, Peter
Howard, Luke S.
Richard, Dominik
Papadakis, Kelly
Mayer, Eckhard
Metadata
Show full item record
Abstract
Background Macitentan is beneficial for long-term treatment of pulmonary arterial hypertension. The microvasculopathy of chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension are similar.
URI
http://hdl.handle.net/20.500.12627/176488
https://doi.org/10.1016/s2213-2600(17)30305-3
Collections